Alkermes shares plunge after drug misses trial goals By: MarketWatch January 21, 2016 at 08:42 AM EST ALKS 5461, a drug that aims to treat clinical depression, failed to meet goals for two of three clinical trials, with a third trial ongoing. Read More >> Related Stocks: Alkermes Plc